Registered title, quoted from ClinicalTrials.gov
A Phase II Study of GFH375 Combined With GFS202A or GFH276 Versus GFH375 in Patients With Previously Treated Locally Advanced Unresectable or Metastatic Pancreatic Cancer Harboring KRAS G12D Mutation
An open trial on pancreatic cancer, registered on ClinicalTrials.gov. The lead sponsor is not a hospital on this site; 1 hospital on this site is listed as study site.
Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.
The study team’s contact details are on the registry record. This site does not pass on enquiries.
Hospitals in mainland China listed for this trial 1
Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.
The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov
Source: ClinicalTrials.gov record NCT07784374, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched
Checklist for this trial 6
Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.
Show the checklist (6 points)Hide the checklist
18 years to 80 years; sex: all
Registered eligibility fields
Histologically or cytologically confirmed pancreatic adenocarcinoma.
Inclusion criterion 3
Has received at least 1 prior line of systemic anti-tumor therapy.
Inclusion criterion 5
Prior treatment with KRAS G12D-specific or pan-RAS/KRAS targeted agents.
Exclusion criterion 3
Has at least one measurable lesion per RECIST version 1.1.
Inclusion criterion 6
Other malignancy that has progressed or required treatment within 3 years prior to study entry.
Exclusion criterion 1
Pregnant or lactating female subjects.
Exclusion criterion 8
Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; day-to-day activity level; blood tests: counts, liver and kidney function.
Questions to ask the study team
Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07784374, read on 10 Nov 2026.
Registered criteria
Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.
Inclusion Criteria:
- Able to provide written informed consent prior to any study-related procedures.
- Male or female subjects aged between 18 and 80 years (inclusive) at the time of informed consent.
- Histologically or cytologically confirmed pancreatic adenocarcinoma.
- Estimated life expectancy ≥ 3 months as judged by the investigator.
- Has received at least 1 prior line of systemic anti-tumor therapy.
- Has at least one measurable lesion per RECIST version 1.1.
- Adequate organ function.
Exclusion Criteria:
- Other malignancy that has progressed or required treatment within 3 years prior to study entry.
- Active central nervous system (CNS) metastases.
- Prior treatment with KRAS G12D-specific or pan-RAS/KRAS targeted agents.
- Clinically significant severe cardiovascular disease.
- Stroke or other severe cerebrovascular events within 6 months prior to randomization.
- Significant acute or chronic infectious disease.
- Severe psychiatric disorder, history of drug abuse, or significant alcohol abuse.
- Pregnant or lactating female subjects.
- Other conditions that, in the investigator's opinion, make the subject unsuitable for study participation.
Quoted from ClinicalTrials.gov, NCT07784374, participation criteria. Read on 10 Nov 2026.
Where this information comes from
The registry record
ClinicalTrials.gov (US National Library of Medicine), record NCT07784374, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.
Diseases and hospitals
The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions
What is left out
Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.